 |
Consilium Strategic Communications is handling the merger of Oculis and European Biotech Acquisition Corp. in a SPAC deal valued in the $220M range. The combined entity will trade on the NASDAQ.
Switzerland-based Oculis is a biopharma company focused on developing treatments to save sight and improve eye care.
Riad Sherif, Oculis CEO, said proceeds from the EBAC transaction will be used to accelerate development of drugs in its pipeline.
EBAC has screened over 100 European biotech companies.
CEO Eduardo Bravo called Oculis a prime example of what his company wants to invest in.
He said Oculis has “great innovation, a well thought-out strategy and an experienced management team to bring promising therapies to market for patients suffering from eye disease.”
Oculis has product candidates to treat macular edema, dry eye disease and nero-retina indicators such as glaucoma.
Consilium Strategic Communications, which works in the healthcare PR and IR space, has Amber Fennell, Matthew Cole and David Daley working the Oculis deal.
Prosek Partners handles New York’s Tilray Brands, craft beer & cannabis operation, as it acquires BrewDog, a leading British independent beer producer in the UK, for $45M.
Brunswick Group handles Zurich Insurance as it agrees to buy UK-based Beazley specialty insurer in a deal valued at $11B.
FGS Global represents Brink’s as it agrees to acquire NCR Atleos, which relies on Collected Strategies, in a $6.6B cash & stock deal to create a leading fintech infrastructure company. (Updated)
A January article in O’Dwyer’s proposes that in 2026, the strongest financial brands will not simply tell compelling stories—they will “signal readiness.”
C Street Advisory Group is working the Chapter 11 filing of Axip Energy Services as it unloads its nearly all of its assets to deal with a heavy debt load.
